WO2009093251A2 - Vaccin contenant un réovirus basé sur une séquence de protéine sigma c - Google Patents

Vaccin contenant un réovirus basé sur une séquence de protéine sigma c Download PDF

Info

Publication number
WO2009093251A2
WO2009093251A2 PCT/IL2009/000098 IL2009000098W WO2009093251A2 WO 2009093251 A2 WO2009093251 A2 WO 2009093251A2 IL 2009000098 W IL2009000098 W IL 2009000098W WO 2009093251 A2 WO2009093251 A2 WO 2009093251A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
seq
peptide
peptides
sigma
Prior art date
Application number
PCT/IL2009/000098
Other languages
English (en)
Other versions
WO2009093251A3 (fr
Inventor
Jacob Pitcovski
Dana Goldenberg
Original Assignee
Gavish-Galilee Bio Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish-Galilee Bio Applications Ltd filed Critical Gavish-Galilee Bio Applications Ltd
Publication of WO2009093251A2 publication Critical patent/WO2009093251A2/fr
Publication of WO2009093251A3 publication Critical patent/WO2009093251A3/fr
Priority to IL207196A priority Critical patent/IL207196A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to novel sigma C proteins from avian reovirus isolates from Israel, peptides derived therefrom, and to broad activity anti-reovirus vaccines.
  • Avian reovirus is a disease agent that causes economic losses in the poultry industry.
  • ARV belongs to the Orthoreovirus genus in the family Reoviridae and was first isolated from birds in 1954 (Fahey and Crawley, 1954). Since then, many variants with broad antigenic diversity have been isolated in many countries.
  • Avian reovirus is the main cause of viral arthritis and tendosynovitis (Robertson and Wilcox, 1986). Damage is also caused by infection of the liver, heart and intestine, and by immunosupression. Birds are most susceptible at young ages (Rosenberger et al, 1989).
  • the available vaccines are the attenuated vaccine strain si 133, developed in 1980, and inactivated vaccines developed in 1985 and 1994. Protection of offspring is conferred by antibodies transferred from maternal flocks that have been vaccinated with the si 133 vaccine (TriReo: Fort Dodge) (Rekik and Silim, 1992; Shapouri et al, 1995; Varela, R., and J. Benavente). In Israel, a vaccine was developed in 1994 using a local isolate (strain 641). This vaccine consists of an inactivated virus injected to maternal flocks. Despite vaccination, birds are not fully protected.
  • the avian reovirus genome consists of 10 fragments of double-stranded
  • RNA of 1 to 4 kb that are divided into large (L), medium (M) and small (S) in accordance to their size.
  • the virus is non-enveloped with a capsid of 70 to 80 nm in diameter (Jokik, 1983; Spandidis and Graham, 1976).
  • the RNA sequence of some Avian reovirus strains has been determined, and the proteins encoded by avian reovirus RNA have been identified (Cashdollar, et al, 1984; McCrae and Joklik, 1978; Schnitzer, 1985; Wickramasinghe et al, 1993).
  • Sigma C protein was found to be encoded in the third open reading frame (ORF) of the Sl fragment (Schnitzer, 1985; Wickramasinghe et al, 1993). This protein is located on the surface of the capsid (Wickramasinghe et al, 1993) and functions in the identification and binding of the virus to the target cell.
  • ORF open reading frame
  • Sigma C is a homotrimer with a tertiary structure consisting of two domains: the "head” domain which is located at the C terminal end of the protein and the “shaft” domain at the N terminal part.
  • Sigma C is a relatively small protein of 326 amino acids (Schnitzer et al, 1982) and its relative amount on the viral capsid is small, as compared to other viral proteins.
  • the importance of sigma C manifests itself at two levels; first, it is the most variable protein of the reovirus (Liu and Giambrone, 1997) and second, it induces the production of neutralizing antibodies.
  • the present invention relates, in one aspect, to a peptide selected from a peptide derived from a conserved region of a sigma C protein of an avian reovirus isolate, and an analog of said peptide.
  • the present invention provides a fusion polypeptide comprising the sequences of at least two peptides derived from reovirus sigma C proteins, wherein each of the at least two peptides has from 5 to 23 amino acid residues, each peptide is bound to the other peptide via a linker comprising 1-3 amino acid residues, the fusion polypeptide comprises at least two copies of each peptide and has a total of 4-16, preferably 6, 8, 10, 12, more preferably, 14, peptide sequences.
  • the present invention also provides an immunogenic composition comprising at least one fusion polypeptide of the invention, with or without an adjuvant.
  • the present invention relates to a sigma C protein (SCP) of an avian reovirus isolate (RI) from Israel, wherein said RI belongs to the Group I, II or III of reovirus as herein defined, and said RIs are selected from ISR521, ISR526. ISR5215, ISR5220, ISR5225, ISR5226 (Group I), ISR522, ISR5217, ISR5221, ISR5222, ISR5223 (Group II); and ISR524, ISR527, ISR528, ISR529, ISR5211, ISR5213 (Group III), or a fraction or fragment of said reovirus SCP.
  • the present invention further provides vaccines comprising one or more of said peptides, fusion polypeptides or SCP and a vaccine comprising at least four inactivated reovirus isolates.
  • Fig. 1 depicts a phylogenetic tree of avian reovirus strains according to the variability in sigma C amino acid sequences.
  • the strains in the squares are isolates from Israel.
  • the Roman numbers I-IV designate the four reovirus isolate (RJ) groups as defined herein.
  • Fig. 2 depicts an antigenic chromatogram for prediction of antigenic sites on the sigma C protein. Peak- antigenic region; Star- conserveed regions and sites conserved among isolates.
  • Fig. 3 shows a bar graph representing an ELISA in which the wells were coated with whole reovirus 1 133.
  • Figs. 4A-4B depict a Western blot showing production in E. coli cells of the fusion polypeptides herein designated R-PEP Al and R-PEP A2.
  • Fig. 4A SDS- PAGE of extract fractions of E. coli expressing R-PEP Al and R-PEP A2. Circles indicate the specific recombinant polypeptides.
  • Fig 4B immunoblot of the gel shown in 3 A using anti-histidine antibodies.
  • Lane 1 R-PEP Al in pellet obtained after spin at 4000rpm; Lane 2, R-PEP Al in pellet obtained after spin at 12000rpm; Lane 3, R-PEP Al in supernatant obtained after spin at 12000rpm; Lane 4, size marker (Ladder Plus, Fermentas); Lane 5, R-PEP A2 in pellet obtained after spin at 4000rpm; Lane 6, R-PEP A2 in pellet obtained after spin at 12000rpm; Lane 7, R- PEP A2 in supernatant obtained after spin at 12000rpm; Lane 8, empty; Lane 9, Negative control, an irrelevant protein expressed in E.coli; Lane 10, empty. Figs.
  • 5A-5B depict immunoblots of R-PEP Al and R-PEP A2, respectively, as antigens, exposed to chicken sera from chicken immunized with R-PEP Al (Lane 6); R-PEP A2 (Lane 5); R-PEP A1+A2 (Lane 4); reovirus (Lane 3); sigma C peptide (Lane 2).
  • Lane 8 size markers; Lane 7, detection with anti-histidine antibodies; Lane 1 , Negative control, an irrelevant protein expressed in E.coli. Arrow points at specifically labeled fusion polypeptide.
  • Fig. 6 shows a dot blot of reovirus (strain si 133) as antigen exposed to chicken sera from chicken immunized with R-PEP Al (Row 1); R-PEP A2 (Row 2); R-PEP A 1+A2 (Row 3); sigma C peptide (Row 4); reovirus (Row 5); Negative control (Row 6).
  • conserved domain refers herein to a domain conserved among the virus variants; namely, the amino acid sequences of the domains are similar but not necessarily absolutely identical to each other. It has also been found herein that at least some of the conserved domains comprise amino acid sequences with characteristics of predicted antigenic sites.
  • the genetically variable avian reovirus strains, or isolates, infecting birds in Israel and elsewhere can be divided into four groups according to the variability in the amino acid sequence of the sigma C protein expressed by the isolates.
  • One member of one of the groups represents only a fraction of the avian reovirus isolates in nature; however, one member of each of the four groups taken together represent many, if not most, variants existing in nature.
  • the four groups of reovirus isolates (RI) are referred to herein as RI Groups I to IV.
  • SCP avian reovirus sigma C proteins
  • the four SCP groups disclosed in Table 2 herein below are based on the sigma C proteins of 19 isolates from Israel and elsewhere as defined using the software mentioned above.
  • the composition of the groups may vary slightly depending on the algorithm and software used to analyze the sequences. The important concept is that each group represents a fraction of the viral population and that single representatives taken from each one of the groups together represent the whole viral population.
  • composition of each of the four groups is not limited to the sequences disclosed in the table, but comprises all amino acid sequences that are at least 75% identical to the sequences of each of the groups in Table 2.
  • SCP of Group IV is not limited to the two sequences SEQ ID NO: 1 and SEQ ID NO: 2, but comprises also additional sequences (that have not been identified) that are at least 75% identical to the sequences of SEQ ID NO: 1 and SEQ ID NO: 2.
  • the invention provides a peptide selected from a peptide derived from a conserved region of a sigma C protein (SCP) of an avian reovirus isolate (RI), and an analog of said peptide.
  • SCP sigma C protein
  • RI avian reovirus isolate
  • peptides of the invention include both the SCP peptides and their analogs.
  • the peptide has from 5 to 30, preferably, 6, 7, 8, 9, 10, 12, 14, 16, 19 amino acid residues.
  • the peptide of the invention is preferably derived from a SCP of an RI from Israel that belongs to one of the four Groups I to IV according to the phylogenetic tree depicted in Fig. 1 herein.
  • the RI from Israel is preferably selected from ISR521, ISR526.
  • ISR5215, ISR5220, ISR5225, ISR5226 Group I
  • ISR522, ISR5217, ISR5221, ISR5222, ISR5223 Group II
  • ISR524, ISR527, ISR528, ISR529, ISR521 1 , ISR5213 Group III
  • 59103, S l 133 Group IV
  • ISR5215, ISR5223, ISR528 and 59103 are also contemplated by the present invention.
  • the peptides of the invention are selected from the peptides of SEQ ID NOs: 3-28 presented in Table 3 herein, more preferably the peptides of SEQ ID NOs: 10, 1 1 , 13-20 and 22.
  • the invention also relates to an analog of a peptide derived from a conserved region of a sigma C protein of an avian reovirus isolate, preferably the peptides of SEQ ID NOs: 29-33 presented in Table 4 herein .
  • the peptide of the invention may be attached to: (i) a carrier protein such as E. coli enterotoxin LT or bovine serum albumin (BSA); (ii) to microbeads carrying an enhancer molecule such as LT; or (iii) to biotin and then to avidin, wherein the avidin may be comprised within microbeads.
  • a carrier protein such as E. coli enterotoxin LT or bovine serum albumin (BSA)
  • BSA bovine serum albumin
  • microbeads carrying an enhancer molecule such as LT or
  • avidin may be comprised within microbeads.
  • These attached peptides are suitable for their use in immunogenic compositions and vaccines and the invention also provides an immunogenic composition or vaccine comprising one or more of said peptides attached to (i), (ii) or (iii) as defined above or any other suitable attachment for their use in immunogenic compositions and vaccines.
  • the synthetic polypeptide referred to herein as a fusion polypeptide, is designed to elicit an optimal immune response. This is achieved by including at least two copies of each domain sequence within the sequence of the fusion polypeptide and by ensuring that the fusion polypeptide acquires a linear configuration in solution.
  • the linear configuration is achieved by inserting a linker composed of 1-3 amino acids, preferably two lysine residues, linking each two peptide sequences.
  • the present invention provides a fusion polypeptide comprising the sequences of at least two peptides derived from reovirus sigma C proteins, wherein each of the at least two peptides has from 5 to 23, preferably 6 to 20, amino acid residues, each peptide is bound to the other peptide via a linker comprising 1-3 amino acid residues, the fusion polypeptide comprises at least two copies of each peptide and has a total of 4-16, preferably 6, 8, 10, 12, more preferably, 14, peptide sequences.
  • the linker between two peptide sequences in the fusion polypeptide is preferably composed of two amino acids and is more preferably Lys-Lys to ensure a linear configuration of the fusion polypeptide in solution.
  • Any reovirus SCP peptide may be used to construct the fusion polypeptide.
  • the conserved peptides of SEQ ID NOs. 3 to 33 presented in Tables 3 and 4 herein are used, more preferably the peptides of SEQ ID NO: 10, 1 1, 13-20 and 22.
  • the fusion polypeptide comprises 6-8, preferably 7 different peptides, each peptide appearing twice, thus the fusion polypeptide has a total of 12- 16, preferably 14 peptide sequences, each two peptides linked by Lys- Lys. In one preferred embodiment, the fusion polypeptide has the Lys-Lys residue also at the N- and C-termini.
  • the fusion polypeptide is of SEQ ID NO:34, herein designated R-PEP Al, which comprises two sequences in tandem of each of the peptides of SEQ ID NOs: 13-17, 20 and 22, and comprises the sequence Lys-Lys at the N- and C-termini and linking each two peptides.
  • the fusion polypeptide R-PEP Al can be represented by the structure:
  • R-PEP A2 which comprises two sequences in tandem of each of the peptides of SEQ ID NOs: 10, 11, 15, and 17-20, and comprises the sequence Lys-Lys at the N- and C-termini and linking each two peptides.
  • the fusion polypeptide R-PEP A2 can be represented by the structure: Lys-Lys-X8- Lys-Lys-X8- Lys-Lys-X9- Lys-Lys-X9- Lys-Lys-X 10- Lys-
  • the present invention also provides an immunogenic composition comprising at least one fusion polypeptide of the invention, with or without an adjuvant.
  • the immunogenic composition comprises the fusion polypeptide R-PEP Al , R-PEP A2 or a mixture thereof, with or without an adjuvant.
  • Any suitable adjuvant can be used such as Freund's complete or incomplete adjuvant, LT, aluminum hydroxide, water-in-oil, oil-in-water, etc.
  • the fusion polypeptide of the invention can be synthesized by methods well known in the art either by peptide chemistry technology or by recombinant techniques starting from specially designed polynucleotides encoding the fusion polypeptide sequence.
  • the invention also provides a polynucleotide encoding a fusion polypeptide as defined herein.
  • the polynucleotide is of the SEQ ID NO:36 or 37 and code for the fusion polypeptides R-PEP Al or R-PEP A2, respectively.
  • bacterial or eukaryotic cells such as yeast or plant cells
  • the expressed fusion polypeptide may be purified using the purification tag inserted into the polypeptide and/or by other protein purification methods well known in the art.
  • the fusion polypeptide is expressed in a bacterial cell, more preferably E. coli.
  • the fusion polypeptide comprises at least two copies of each one of at least two conserved immunogenic domains, wherein said at least two copies of each conserved immunogenic domain appear in tandem.
  • the repeating occurrences of a certain domain are preferably ordered in tandem, since two adjacent copies of said domain may bind to the same multivalent antibody molecule and thus enhance the immunogenicity of said domain by increasing the avidity of the binding.
  • the fusion polypeptide may be combined with a carrier protein such as, but not limited to, E. coli heat labile enterotoxin (LT), bovine serum albumin and flagellin.
  • LT E. coli heat labile enterotoxin
  • bovine serum albumin bovine serum albumin
  • flagellin The carrier protein may be fused to the N- or the C terminus of the fusion polypeptide or it may flank the fusion polypeptide on both ends.
  • the carrier protein may be fused to the fusion polypeptide by recombinant techniques, i.e. the fusion polypeptide and the carrier protein are encoded by a single nucleic acid sequence and are expressed as a continuous polypeptide.
  • the fusion polypeptide and the carrier protein may be produced separately and then chemically attached to each other.
  • the preferred carrier protein for all aspects of the present invention is the LT protein. It confers the function of carrier and is also known as a powerful adjuvant in injection and oral administration that is capable of eliciting strong systemic IgG and local IgA responses as well as cytotoxic helper T-cell response. Since the reovirus is a mucosal antigen, it is preferential to stimulate the immune response of the mucosal system. IgA antibodies developed by oral vaccinations in mucosal tissues are the main deterrents against the challenge offered by mucosal antigens.
  • the LT protein is a hexamer that consists of two subunits: the 27-kDa catalytic A domain (LTA) anchored in a ring of five identical 1 1.6-kDa B subunits (LTBs).
  • LTA 27-kDa catalytic A domain
  • LTBs five identical 1 1.6-kDa B subunits
  • the Al fragment is toxic and catalyzes the transfer of an ADP-ribose from NAD to stimulatory ⁇ -subunits of G proteins (Gs ⁇ ).
  • Gs ⁇ stimulatory ⁇ -subunits of G proteins
  • LT To use LT as an immunostimulator in animals, its toxicity may be neutralized by mutations, such as the LTK63 mutant of the A subunit (Partidos et al.,1996). Either one of the A and B subunits may be used in conjunction with the fusion polypeptide of the invention.
  • the fusion polypeptide may also be attached to physiologically acceptable microbeads, which may carry enhancer molecules such as LT in addition to the fusion polypeptide.
  • the fusion polypeptide may be bound indirectly to the carrier via antibodies or biotinylated fusion polypeptides may be bound to the carrier via avidin or streptavidin.
  • Microparticles intended for use in the present invention preferably have a size in the range from 10 nm to 200 ⁇ m.
  • the size chosen for a particular microparticle will depend on the active agent to be delivered, and the intended route of administration.
  • particles are conveniently in the size range 0.5 to 5.0 ⁇ m.
  • a suitable size is less than lOO ⁇ m.
  • Microparticles for parenteral delivery conveniently have a size of less than 200 ⁇ m, preferably less than 150 ⁇ m.
  • the fusion polypeptide may comprise a purification tag, which is preferably a His-tag (e.g. His 6 ), but may also be a (His-Asn) 6 tag, a Flag tag, or any other tag that may facilitate the purification of the fusion polypeptide.
  • a sole tag can be used or different tags can be used in combination.
  • the tag(s) can be fused to the C-terminus or the N-terminus of the fusion polypeptide.
  • the optimal induction of a protective immune response may be obtained by presenting to immuno-reactive cells such as B and T-cells at least two epitopes that may interact with the multivalent receptors on the cells' surface.
  • the polypeptide has to be in a linear configuration and not folded upon itself.
  • Two features of the fusion polypeptide ensure that this is the case.
  • two lysine residues are interspersed in between each domain in the amino acid sequence of the fusion polypeptide.
  • the positively charged lysine residues repulse each other and ensure that the polypeptide chain does not fold.
  • this is true as long as the length of the polypeptide chain does not exceed a certain limit.
  • the maximum size of such a protein is approximately 5OkD.
  • a further finding in accordance with the present invention is that even if the chimeric protein is packed in inclusion bodies of E. coli cells that are used to vaccinate birds, it is capable of eliciting a beneficial immune response.
  • the fusion polypeptide of the invention is capable of eliciting a specific B-cell and/or T-cell response in a bird. Specifically, T-helper cells and cytotoxic T cells are induced.
  • the present invention relates to a sigma C protein (SCP) of an avian reovirus isolate (RI) from Israel, wherein said RI belongs to the Group I, II or III of reovirus as herein defined, and said RIs are selected from ISR521, ISR526. ISR5215, ISR5220, ISR5225, ISR5226 (Group I), ISR522, ISR5217, ISR5221, ISR5222, ISR5223 (Group II); and ISR524, ISR527, ISR528, ISR529, ISR521 1 , ISR5213 (Group III), or a fraction or fragment of said reovirus SCP.
  • the invention provides the recombinant SCPs of SEQ ID NO: 38 of RI ISR5223, SEQ ID NO:39 of RI ISR5215 and SEQ ID NO:40 of RI ISR528.
  • the invention also provides a polynucleotide encoding a reovirus sigma C protein of the invention.
  • the polynucleotide is of SEQ ID NOs. 41 , 42 or 43, which code for the SCPs of SEQ ID NOs: 38, 39, and 40, respectively.
  • these fragments include SEQ ID NO:44 (ISR521 ), SEQ ID NO:45 (ISR522), SEQ ID NO:46 (ISR524), SEQ ID NO:47 (ISR525), SEQ ID NO:48 (ISR526), SEQ ID NO:49 (ISR527), SEQ ID NO:50 (ISR528), SEQ ID NO:51 (ISR529), SEQ ID NO:52 (ISR5210), SEQ ID NO:53 (ISR521 1), SEQ ID NO:54 (ISR5212), SEQ ID NO:55 (ISR5213), SEQ ID NO:56 (ISR5215), SEQ ID NO:57 (ISR5217), SEQ ID NO:58 (ISR5219), SEQ ID NO:59 (ISR5220), SEQ ID NO:60 (ISR5221 ), SEQ ID NO:61 (ISR5222), SEQ ID NO:62 (ISR5223), SEQ ID NO:63 (ISR5224), SEQ ID NO:44 (
  • the sigma C proteins of the new isolates ISR 523, ISR5216 and ISR 5218 were found to be identical to the sequences of ISR522 (SEQ ID NO:5), ISR5215 (SEQ ID NO:59) and ISR5217 (SEQ ID NO:57), respectively.
  • the partial sequences of the strains 59103 (SEQ ID NO: 1) and si 133 (SEQ ID NO:2) are known.
  • the invention provides a vaccine comprising at least one recombinant sigma C protein (SCP) of an avian reovirus isolate (RI) from Israel of each of Groups I, II, III or IV of reovirus as herein defined, optionally together with an adjuvant.
  • the RI is selected from ISR521, ISR526. ISR5215, ISR5220, ISR5225, ISR5226 (Group I), ISR522, ISR5217, ISR5221, ISR5222, ISR5223 (Group II); ISR524, ISR527, ISR528, ISR529, ISR5211, ISR5213 (Group III); and 59103 and Sl 133 (Group IV).
  • the vaccine may comprise one recombinant SCP or a mixture of 2, 3 or 4 or more SCPs, each representative of one of the groups I, II, III or IV.
  • the vaccine comprises at least one representative of each group I, II, III and IV.
  • the vaccine comprises a mixture of the (i) recombinant SCP of Group I of the SEQ ID NO: 38; (ii) recombinant SCP of Group II of the SEQ ID NO: 39; (iii) recombinant SCP of Group III of the SEQ ID NO: 40; and (iv) recombinant SCP of Group IV of SEQ ID NO: 68.
  • the invention relates to a reovirus vaccine comprising at least one of the new reovirus isolates ISR521, ISR526. ISR5215, ISR5220, ISR5225, ISR5226, ISR522, ISR5217, ISR5221, ISR5222, ISR5223, ISR524, ISR527, ISR528, ISR529, ISR521 1 , and ISR5213 in inactivated form, or a mixture thereof that may include also known strains such as 59103 and si 133.
  • the vaccine may optionally contain an adjuvant.
  • the vaccine composition comprises one variant of each RI group; each variant being the most representative variant of its group, i.e. each variant expresses a sigma C protein that has the highest identity to the sigma C proteins expressed by the known members of the group.
  • the vaccine comprises at least four inactivated reovirus isolates (RI), each RI belonging to one of the Groups I, II, III or IV of reovirus as herein defined, optionally together with an adjuvant.
  • the vaccine comprises RIs ISR521 , ISR526. ISR5215, ISR5220, ISR5225, ISR5226 (Group I), ISR522, ISR5217, ISR5221, ISR5222, ISR5223 (Group II); ISR524, 1SR527, ISR528, ISR529, ISR521 1 , ISR5213 (Group III); and 59103, Sl 133 (Group IV).
  • the vaccine comprises a mixture of the isolates ISR5215 (Group I), ISR5223 (Group II), ISR528 (Group III), and 59103 (Group IV).
  • the production of the inactivated avian reovirus isolates is carried out by methods well-known in the art, preferably in Vero cells or in embryonic chick eggs, e.g., in allantoic cavity of 11-day-old embryonated Specific Pathogen Free (SPF) hen eggs.
  • the invention provides the new reovirus isolates 1SR521,
  • ISR526 ISR5215, ISR5220, ISR5225, ISR5226, ISR522, ISR5217, ISR5221 , ISR5222, ISR5223, ISR524, ISR527, ISR528, ISR529, ISR5211, and ISR5213.
  • the sigma C protein is located on the outer part of the capsid and functions in the identification and binding of the virus to the target cell.
  • a vaccine comprising all variable regions of the sigma C protein presented on the capsid of inactivated viral particles.
  • the four RI groups disclosed in Table 2 herein below are based on the sigma C proteins expressed by 19 isolates from Israel and elsewhere.
  • the composition of each of the four groups is not limited to the variants/isolates disclosed in the table, but comprises all variants expressing sigma C protein amino acid sequences that are at least 75% identical to the sigma C polypeptides expressed by variants of each of the groups in Table 2.
  • RJ group 4 is not limited to the two isolates 59103 and S l 133, but comprises also variants (that have not been isolated) that express sigma C proteins that are at least 75% identical to the sequences of sigma C proteins expressed by 59103 and S l 133.
  • the invention also contemplates a DNA or RNA vaccine comprising a polynucleotide of the invention or an expression vector comprising said (deoxy)polynucleotide.
  • the immunogenic compositions/vaccines of the present invention whether they comprise at least one inactivated RI, at least one reovirus recombinant sigma C protein, a fusion polypeptide comprising conserved domains of the reovirus sigma
  • C protein or a conserved peptide are capable of conferring protection in mammals, including humans, or birds, against all known avian reovirus variants.
  • the invention further relates to a method for inducing an avian immune response conferring protection against reovirus, which comprises administering a vaccine or immunogenic composition according to the invention.
  • the composition may be administered by any suitable route of administration such as by injection, intradermally or orally to birds via the drinking water.
  • Virus was isolated from the tendon of infected birds.
  • the viral RNA was extracted (protocols were performed according to QlAamp Viral RNA- Mini Kit, Qiagen, USA).
  • the sigma C gene was amplified by RT-PCR: 1 ⁇ l of purified dsRNA was denatured in boiling water for 10 min, chilled on ice for 5 min, and then used as template; dsRNA was used to generate cDNA by reverse transcription and polymerase chain reaction.
  • PCR reactions were subjected to 35 cycles consisting of denaturation for 1 min at 94°C, annealing for 2 min at 42 0 C, and extension for 1 min at 72°C, and one final extension cycle at 74°C for 15 min.
  • the PCR product namely, the sigma C protein, was purified (protocols were performed according to QIAGEN Gel Extraction Kit) and sequenced.
  • Partial sequences of sigma c of isolates 5215, 5223, 528 and 59103 were determined. To each sequence, flanking regions were added to the 5' and 3' end in order to ensure correct folding and maintain protein structure. Furthermore, the added sequence introduced restriction sites to enable cloning into pQE30 plasmid, inserting the coding sequence in the correct position relative to the promoter and in frame.
  • the designed genes were manufactured by GenScript (USA) and supplied in pQE30 plasmid. The plasmid is transformed into E. coli JM 109 and the produced proteins purified and used for vaccination..
  • the sequences of the full recombinant proteins and the nucleic acids encoding them are disclosed throughout the present specification.
  • the restriction sites introduced into the four recombinant proteins disclosed herein were Kpnl and Pstl.
  • RNA sequences of sigma C of 30 isolates of avian reovirus from infected birds in Israel were determined and the amino acid sequences were deduced (SEQ ID NO: 1
  • Group I comprises the RIs ISR521, ISR526.
  • Group IV comprises the RIs 59103 and Sl 133.
  • a vaccine based on the whole inactivated viruses comprising four isolates representatives of each of the four Groups I to IV, the RIs ISR5215 (Group I), ISR5223 (Group II), ISR528 (Group III) and ISR59103 (Group IV), all marked in bold in Table 2, is used as Anti Reovirus Broad Activity (ARBA).
  • the viruses are propagated separately in Vero cells, inactivated by overnight incubation in 0.3-0.5% formalin and mixed with adjuvant.
  • the experiment includes seven groups of birds: 1. Positive control (si 133); 2. Negative control (PBS); 3-6.
  • the vaccine administered to Group 7 contains and displays all common conserved region sequences of sigma C.
  • VN Virus Neutralization
  • the birds are then challenged with a homologous virus or a mixture of viruses from the 4 genetic groups.
  • the deduced amino acid sequence of sigma C was determined.
  • SCP representative sigma C protein
  • the complete sequence of the representative sigma C protein (SCP) of each of the Groups I, II and III, namely, the strains ISR5215 (Group I), ISR5223 (Group IT) and ISR528 (Group III) was deduced.
  • Their amino acid sequences are represented by SEQ ID NOs: 56, 62 and 50, respectively.
  • the recombinant sigma C proteins derived from these sequences, were designated as SCP Group I (SEQ ID NO:39), SCP Group II (SEQ ID NO:38), SCP Group III (SEQ ID NO:40).
  • SCP Group IV The full sequence of the SCP of RI 59103, previously designated R99, (Group IV) is represented by SEQ ID NO: 1. This sequence was determined at the laboratory of the main inventor and has been submitted to GenBank, accession no. AY332520 (Vasserman et al, 2004).
  • SCP Group IV The recombinant SCP derived from SEQ ID NO: 1 (SCP Group IV) is represented by SEQ ID NO: 68.
  • SEQ ID NOs: 41-43 and 69 polynucleotide sequences encoding for the proteins were designed by the inventors as described above in Materials and Methods (iv). The desired genes for expression in E.
  • E. coli were manufactured by GenScript (USA) and supplied in pUC57 plasmid. The gene was transferred to pAL plasmid and transformed into E. coli JM 109 (Invitrogen, San Diego, CA). The expression of the recombinant proteins in E. coli was carried out by the inventors as described (Vasserman et al., 2004). The recombinant sigma C protein was isolated from the bacterial cells and purified. For the preparation of the vaccine, the four purified recombinant sigma C proteins of SEQ ID NOs: 38-40 and 68 are mixed and used with or without an adjuvant. The vaccine contains and display all common conserved region sequences of sigma C. In one example, SPF chicks (SPAFAS, USA) are divided into groups and each group was vaccinated twice with partially purified protein (lmg/ml) intramuscularly or orally (50-150 ⁇ g/dose).
  • Table 3 shows the sequences of 26 new peptides of the invention of SEQ ID NOs: 3-28 with amino acid sequences comprised within the conserved regions of sigma C proteins of avian reovirus isolates.
  • the peptides presented in Tables 3 and 4 may be produced synthetically or using recombinant techniques and may be used for vaccinating birds to confer broad protection.
  • Vaccine comprising a peptide from Table 3 or 4 bound to a carrier protein such as E. coli enterotoxin LT or bovine serum albumin (BSA).
  • a carrier protein such as E. coli enterotoxin LT or bovine serum albumin (BSA).
  • Vaccine comprising a mixture of 2 or more peptides from Table 3 or 4 bound to a carrier protein such as LT or BSA.
  • Vaccine comprising a peptide from Table 3 or 4 chemically synthesized with biotin attached to the N-terminus as done for peptides of SEQ ID NOs: 3-12 in Table 3 and then bound to avidin that serves as a carrier to enhance immune response.
  • Vaccine comprising one or more peptides from Table 3 or 4 bound to microbeads carrying an enhancer molecule, such as avidin, in which case the peptide is biotinylated, or LT. 5.2. Inimunogenicity of the peptides.
  • the peptides of SEQ ID NOs: 3, 5, 8 and 11 were attached to a carrier protein, in this case BSA, to form a peptide conjugate.
  • a carrier protein in this case BSA
  • the peptide conjugates were injected intramuscularly in four groups of ten 3 weeks old chicks, and after two weeks a boost of peptide conjugates in Freund's incomplete adjuvant was injected.
  • Example 6 Fusion polypeptides comprising peptides derived from avian sigma C proteins and production thereof
  • fusion polypeptides herein designated R-PEP Al and R-PEP A2, comprising sequences of reovirus sigma C protein peptides depicted in Table 3, were prepared. Each peptide appears twice in the polypeptide in order to amplify the immunogenicity of the molecule, and each two peptides are separated by two lysine residues to enable a linear structure.
  • the fusion polypeptide comprises two lysine residues at the N-terminus and at the C-terminus.
  • R-PEP A 1 is a polypeptide comprising the sequences of 7 reovirus sigma C peptides arranged from the N-terminus to the C-terminus in the following order: the peptides 20, 1 1, 12, 13, 14, 18 and 15 as presented in Table 3. Each sequence appears twice, and sequence pair is intercalated by two lysine residues.
  • R-PEP Al has the following sequence (SEQ ID NO: 34):
  • R-PEP A2 is a polypeptide comprising the sequences of 7 reovirus sigma C peptides arranged in the same manner as described for R-PEP Al .
  • the peptides appearing in R-PEP A2 are 8. 16, 9. 13, 17. 18 and 15 as presented in Table 3
  • R- PEP A2 has the following sequence (SEQ ID NO: 35):
  • the general design of the gene is: KpnI-6Xhis-BamHI-R-PEP-BglII-6Xhis-Stop-PstI, where Kpnl, BamHI, BgIII and Pstl designates restriction enzyme recognition sequences, His is the codon for Histidine (CAT) and Stop designates TAA.
  • Six histidine residues are added to the N or C terminal part of R-PEP for the purpose of purification on a nickel column (e.g. Quagen Ni-NTA Agarose resin).
  • the Optimization Region for R-PEP Al was 31 - 552, and for R-PEP A2 it was 31 - 483.
  • the GC Range for both proteins was 30 - 70.
  • the R-PEP gene was designed according to the E.coli codon usage.
  • R-PEP A2 were inserted into the expression vector PQE-30 (Qiagen) at the Kpnl and Pstl restriction sites, and E.coli cells were transformed with the purified expression vector using methods well known in the art.
  • Extracts of the transformed bacteria were fractionated by centrifugation and detected by SDS-PAGE as shown in Fig. 4A.
  • the proteins were transferred to Hybond-c Nitrocellulose membrane (Amersham), stained with anti-histidine antibodies and detected by Western blot with anti-histine antibodies and visualized with diaminobenzidine tablets (Sigma) (Fig. 4B).
  • the labeled bands correspond to the expected molecular weights of the two fusion polypeptides which is 20 kDa and 17.7 kDa for R-PEP Al and R-PEP A2, respectively.
  • each one of R-PEP Al and R-PEP A2 is recognized by sera from birds immunized with the respective antigen and by sera from birds immunized with R-PEP A1+A2, chicken anti-reovirus (si 133) and chicken anti- sigma C (produced in the laboratory of the inventors), but not with sera from birds immunized with the specific peptide not used as antigen in the immunoblot.
  • the immunblot containing the R-PEP Al peptide did not bind anti-R-PEP A2 sera, and vice versa. This shows that the R-PEP Al and R-PEP A2 peptides are immunogenic and that the sera raised against these antigens are specific.
  • Vaccines comprising R-PEP Al and/or R-PEP A2 are injected intramuscularly along with 0.5 ml of commercial Freund's incomplete adjuvant, but other adjuvants may be used.
  • the birds are grown from day 1 in a positively pressured isolator.
  • SPF chickens are vaccinated twice, at the age of 3 and 7 weeks or a similar schedule.
  • Blood is collected at, for example, 7 and 9 weeks of age and sera is tested by Virus Neutralization (VN) in embryonate eggs and in Vero cells, by ELISA for antibody titer, or other methods.
  • VN Virus Neutralization
  • Varela, R., and J. Benavente Protein coding assignment of avian reovirus S l 133 strain. J. Virol. 68:6775-6777. 1994.
  • Vasserman Y Eliahoo D, Hemsani E, Kass N, Ayali G, Pokamunski S, Pitcovskiad J. The influence of reovirus sigma C protein diversity on vaccination efficiency. Avian Dis. 2004 Apr-Jun;48(2):271-8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un peptide dérivé d’une région conservée d’une protéine sigma C d’un isolat de réovirus aviaire, et un analogue dudit peptide, ainsi que des vaccins anti-réovirus à large spectre d’activité contenant ledit peptide.
PCT/IL2009/000098 2008-01-24 2009-01-25 Vaccin contenant un réovirus basé sur une séquence de protéine sigma c WO2009093251A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL207196A IL207196A0 (en) 2008-01-24 2010-07-25 Reovirus vaccine based on sigma c protein sequence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2314608P 2008-01-24 2008-01-24
US61/023,146 2008-01-24

Publications (2)

Publication Number Publication Date
WO2009093251A2 true WO2009093251A2 (fr) 2009-07-30
WO2009093251A3 WO2009093251A3 (fr) 2009-10-22

Family

ID=40848562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000098 WO2009093251A2 (fr) 2008-01-24 2009-01-25 Vaccin contenant un réovirus basé sur une séquence de protéine sigma c

Country Status (1)

Country Link
WO (1) WO2009093251A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140146803A (ko) * 2013-06-18 2014-12-29 주식회사 단바이오텍 가금 레오바이러스 시그마 c 단백질의 항원 결정기를 포함하는 재조합 단백질 및 이에 대한 항체
WO2016050961A1 (fr) 2014-10-03 2016-04-07 Intervet International B.V. Vaccin à large spectre contre le réovirus aviaire
CN106232808A (zh) * 2014-01-29 2016-12-14 乔治亚大学研究基金公司 禽类呼肠孤病毒疫苗
WO2017118977A1 (fr) * 2016-01-07 2017-07-13 Gavish-Galilee Bio Applications, Ltd Polypeptide optimisé pour un vaccin sous-unitaire contre le réovirus aviaire
CN116120468A (zh) * 2023-03-16 2023-05-16 扬州优邦生物药品有限公司 一种预防禽呼肠孤病毒的病毒样颗粒疫苗及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
WO2000037487A1 (fr) * 1998-12-19 2000-06-29 Merck Patent Gmbh INHIBITEURS DE L'INTEGRINE $G(a)v$G(b)¿6?
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
WO2001096377A2 (fr) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccin contre les tremblements congenitaux du porc
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
WO2004031211A2 (fr) * 2002-10-03 2004-04-15 Epimmune Inc. Peptides de liaison hla et utilisations de ces derniers
WO2005110456A2 (fr) * 2004-05-11 2005-11-24 Abgenomics Corporation Epitopes induisant la mort des lymphocytes t
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
WO2000037487A1 (fr) * 1998-12-19 2000-06-29 Merck Patent Gmbh INHIBITEURS DE L'INTEGRINE $G(a)v$G(b)¿6?
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2001096377A2 (fr) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccin contre les tremblements congenitaux du porc
WO2004031211A2 (fr) * 2002-10-03 2004-04-15 Epimmune Inc. Peptides de liaison hla et utilisations de ces derniers
WO2005110456A2 (fr) * 2004-05-11 2005-11-24 Abgenomics Corporation Epitopes induisant la mort des lymphocytes t

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU CHIEN J ET AL: "Development and characterization of monoclonal antibodies against avian reovirus .sigma.C protein and their application in detection of avian reovirus isolates" AVIAN PATHOLOGY, HUNTINGDON, CAMBS, GB, vol. 35, no. 4, 1 August 2006 (2006-08-01), pages 320-326, XP008107192 ISSN: 0307-9457 *
VASSERMAN Y ET AL: "The influence of reovirus sigma C protein diversity on vaccination efficiency" AVIAN DISEASES, AMERICAN ASSOCIATION OF AVIAN PATHOLOGISTS, KENNET SQ., PA, US, vol. 48, no. 2, 1 April 2004 (2004-04-01), pages 271-278, XP008107191 ISSN: 0005-2086 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101600959B1 (ko) 2013-06-18 2016-03-08 단국대학교 산학협력단 가금 레오바이러스 시그마 c 단백질의 항원 결정기를 포함하는 재조합 단백질 및 이에 대한 항체
KR20140146803A (ko) * 2013-06-18 2014-12-29 주식회사 단바이오텍 가금 레오바이러스 시그마 c 단백질의 항원 결정기를 포함하는 재조합 단백질 및 이에 대한 항체
US10588958B2 (en) 2014-01-29 2020-03-17 University of Georgia Research Foundations, Inc. Avian reovirus vaccines
KR102340265B1 (ko) 2014-01-29 2021-12-15 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 조류 레오바이러스 백신
CN106232808A (zh) * 2014-01-29 2016-12-14 乔治亚大学研究基金公司 禽类呼肠孤病毒疫苗
US11090377B2 (en) 2014-01-29 2021-08-17 University Of Georgia Research Foundation, Inc. Avian reovirus vaccines
EP3099789A4 (fr) * 2014-01-29 2017-09-13 University Of Georgia Research Foundation, Inc. Vaccins contre les réovirus aviaires
US9968671B2 (en) 2014-01-29 2018-05-15 University Of Georgia Research Foundation, Inc. Avian reovirus vaccines
KR20210022165A (ko) * 2014-01-29 2021-03-02 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 조류 레오바이러스 백신
US20180326043A1 (en) * 2014-10-03 2018-11-15 Intervet Inc. Broad-spectrum vaccine against avian reovirus
WO2016050961A1 (fr) 2014-10-03 2016-04-07 Intervet International B.V. Vaccin à large spectre contre le réovirus aviaire
EP3400236A4 (fr) * 2016-01-07 2019-01-23 Gavish-Galilee Bio Applications, Ltd Polypeptide optimisé pour un vaccin sous-unitaire contre le réovirus aviaire
AU2017204942B2 (en) * 2016-01-07 2020-11-26 Gavish-Galilee Bio Applications, Ltd Optimized polypeptide for a subunit vaccine against avian reovirus
CN108431025A (zh) * 2016-01-07 2018-08-21 加维什-加利里生物应用有限公司 用于抗禽呼肠孤病毒亚单元疫苗的优化多肽
WO2017118977A1 (fr) * 2016-01-07 2017-07-13 Gavish-Galilee Bio Applications, Ltd Polypeptide optimisé pour un vaccin sous-unitaire contre le réovirus aviaire
US11541111B2 (en) 2016-01-07 2023-01-03 Gavish-Galilee Bio Applications, Ltd. Optimized polypeptide for a subunit vaccine against avian reovirus
CN116120468A (zh) * 2023-03-16 2023-05-16 扬州优邦生物药品有限公司 一种预防禽呼肠孤病毒的病毒样颗粒疫苗及其制备方法
CN116120468B (zh) * 2023-03-16 2023-09-08 扬州优邦生物药品有限公司 一种预防禽呼肠孤病毒的病毒样颗粒疫苗及其制备方法

Also Published As

Publication number Publication date
WO2009093251A3 (fr) 2009-10-22

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
CN111218459B (zh) 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
Smith et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
ES2597439T3 (es) Antígenos recombinantes del VSR
CA2673373C (fr) Proteine f du virus respiratoire syncytial (rsv), et son utilisation
Both et al. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc
HUT65366A (en) Expression of specific immunogens using viral antigens
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP2016501850A (ja) 口蹄疫（ｆｍｄ）に対する合成ペプチドベースの緊急ワクチン
Wei et al. Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice
EP2532363B1 (fr) Utilisation de flagellines du genre marinobacter en tant qu'adjuvants vaccinaux
Tian et al. The immunoreactivity of a chimeric multi-epitope DNA vaccine against IBV in chickens
WO2022003119A1 (fr) Vaccin contre un coronavirus à réaction croisée
WO2009093251A2 (fr) Vaccin contenant un réovirus basé sur une séquence de protéine sigma c
Goldenberg et al. Optimized polypeptide for a subunit vaccine against avian reovirus
US10117923B2 (en) Production of an immunogen using a plant virus
AU2022279442A1 (en) Optimized polypeptide for a subunit vaccine against avian reovirus
US10881722B2 (en) Epizootic hemorrhagic disease vaccine
ES2267553T3 (es) Secuencias de acidos nucleicos y de aminoacidos del virus de la anemia infecciosa del salmon y sus usos como vacunas.
Wu et al. DNA vaccine against Taenia solium cysticercosis expressed as a modified hepatitis B virus core particle containing three epitopes shared by Taenia crassiceps and Taenia solium
Wu et al. Yeast-derived sigma C protein-induced immunity against avian reovirus
Chandran et al. Display of neutralizing epitopes of Canine parvovirus and a T-cell epitope of the fusion protein of Canine distemper virus on chimeric tymovirus-like particles and its use as a vaccine candidate both against Canine parvo and Canine distemper
JPH02223594A (ja) ヒトライノウイルスペプチド
GB2461832A (en) Methods of treating measles infectious disease in mammals
ES2267510T3 (es) Acidos nucleicos y polipeptidos de lisavirus quimericos.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 207196

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09703950

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09703950

Country of ref document: EP

Kind code of ref document: A2